Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma

Michelle Kinder; Nizar J Bahlis; Fabio Malavasi; Bart De Goeij; Alexander Babich; Jocelyn Sendecki; Joshua Rusbuldt; Kevin Bellew; Colleen Kane; Niels W C J Van de Donk

doi:10.3324/haematol.2020.268656

Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma

Haematologica. 2021 Jul 1;106(7):2004-2008. doi: 10.3324/haematol.2020.268656.

Affiliations

¹ Janssen Research and Development, LLC, Spring House, PA.
² University of Calgary, Arnie Charbonneau Cancer Institute, Calgary.
³ Department of Medical Science, University of Turin, Turin, Italy, and Fondazione Ricerca Molinette, Turin.
⁴ Genmab B.V., Utrecht.
⁵ Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam. n.vandedonk@amsterdamumc.nl.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

ADP-ribosyl Cyclase 1
Antibody-Dependent Cell Cytotoxicity
Humans
Multiple Myeloma*

Substances

ADP-ribosyl Cyclase 1

Grants and funding

Funding: the analysis was funded by Janssen Global Services, LLC; editorial and medical writing support were provided by Tara Abraham, PhD, and Grace Wang, PharmD, of MedErgy, and were funded by Janssen Global Services, LLC.